AI pharmacy chatbot for adults with high blood sugar, blood pressure, or cholesterol in Hong Kong
Official title: Developing an AI Pharmacy Chatbot for the Population of Hong Kong
Run by The University of Hong Kong · NCT07037563 · Data updated 2026-11-12
We will test a WhatsApp AI pharmacy chatbot that answers Hospital Authority–prescribed medication questions for adults in Hong Kong with hyperglycaemia, hypertension, or hyperlipidaemia and their caregivers.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 280 (estimated) |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 2 sites (Hong Kong and 1 other locations) |
| Status | Recruiting |
| Started | June 2025 |
| Main results expected | October 31, 2026 |
| Study ends | October 31, 2026 |
| Registry record updated | June 25, 2025 |
| Trial ID | NCT07037563 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) in Hong Kong who are prescribed Hospital Authority medications for hyperglycaemia, hypertension, or hyperlipidaemia, or their adult caregivers, are eligible to participate.
✕Probably not a fit
People who cannot use WhatsApp, who are not prescribed HA medications for the listed conditions, or whose questions fall outside the chatbot's validated scope may not receive benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The team will build an AI chatbot using natural language processing and the Hospital Authority drug database, incorporating input from the Chief Pharmacist's Office. A proof-of-concept phase with HA pharmacists will validate and refine the chatbot's medication answers. Then at least 280 patients or caregivers will be recruited and randomised to use the chatbot on WhatsApp for seven days or to a control group with no chatbot access. Primary outcomes include user satisfaction, medication adherence, medication knowledge, and pharmacist consultation time, with power calculated to detect an increase in adherence from about 62% to 80%.
Why it matters
Potential benefit: If successful, the chatbot could provide quick, validated medication answers that improve patient knowledge and adherence while reducing time spent with pharmacists.
How similar studies have gone: Previous health chatbot studies have shown promise for improving information access and adherence in some settings, but pharmacy chatbots linked to hospital drug databases remain relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 years or older diagnosed with either hyperglycaemia, hypertension, or hyperlipidaemia, and currently receiving medication prescribed by the Hospital Authority in Hong Kong. * Caregivers aged 18 years or older for patients described above. Exclusion Criteria: * There is no exclusion criterion, but they should meet the inclusion criteria above.
Where it's running
-
Laboratory of Data Discovery for Health
Hong Kong, Hong Kong Recruiting -
The University of Hong Kong
Hong Kong, Hong Kong Recruiting
Study contacts
- Principal investigator: Joseph Wu, PhD — The University of Hong Kong
- Study coordinator: Joseph Wu, PhD
- Email: hkusph@hku.hk
- Phone: +852 3917 6709
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pharmacist-led care pathway for type 2 diabetes in Alberta community pharmacies
This project will test whether a pharmacist-led care pathway in community pharmacies can help adults with type 2 diabetes and HbA1c above 7.0% lower their blood sugar and improve care compared with usual physician or nurse practitioner care.
-
Using low-dose aspirin after preeclampsia to improve recovery
This study is testing if taking low-dose aspirin for six months after having preeclampsia can help new moms recover better by improving their blood pressure and blood vessel function.
-
AI-assisted whole-course management for safe medicine use in advanced solid tumors
A real-world study compares a smartphone-based digital management system with usual care to see if it reduces drug-related problems and healthcare needs for adults with advanced solid tumors receiving cancer therapy.
-
IMB-guided health education to boost medication taking and blood pressure control in adults with hypertension
This study tests a health-literacy program based on Information-Motivation-Behavioral Skills to help adults with hypertension who don’t take their medicines regularly to take them more consistently and better control their blood pressure.
-
Renal Nerve Stimulation to Help Blood Pressure in AF and HFpEF
This study tests whether stimulating the kidneys with a catheter can safely lower blood pressure in adults with atrial fibrillation and HFpEF who also have hypertension.
-
Hypertension: Does Education Help Patients Manage Blood Pressure Better?
This study tests whether structured patient education improves blood pressure control and self-management in adults with hypertension who speak Turkish.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.